血友病患者COVID-19结局:基于美国全国COVID-19监测登记系统的结果
该回顾性队列研究利用美国全国COVID-19登记数据(2020年1月至2022年1月),按1:3倾向性评分匹配比较300例男性血友病患者与900例无血友病对照者的结局。血友病未降低不良结局或静脉血栓栓塞风险,但住院和出血风险增加。
要点
- 匹配队列中血友病患者30天全因死亡和静脉血栓栓塞与对照无显著差异。
- 血友病患者住院风险(OR 1.58)和非中枢神经系统出血风险(OR 4.78)增加。
- 血友病患者发生静脉血栓栓塞与既往静脉血栓栓塞诊断、抗凝治疗和肺部疾病相关。
核心结论
- 调整患者特征和合并症后,血友病增加COVID-19出血风险,但未提供针对重症和静脉血栓栓塞的保护。
研究设计与样本
- 1:3倾向性评分匹配的回顾性队列研究,使用美国全国COVID-19登记数据(2020年1月至2022年1月),比较300例男性血友病患者与900例匹配的无血友病对照者。
主要发现
- 血友病患者中,高龄、心力衰竭、高血压、癌症/恶性肿瘤、痴呆、肾脏和肝脏疾病是重症COVID-19和/或30天全因死亡的风险因素,非中枢神经系统出血也是不良结局的额外风险因素。
- 血友病患者发生COVID-19相关静脉血栓栓塞与既往静脉血栓栓塞诊断(OR 51.9;95%CI 12.8-266;p<.001)、抗凝治疗(OR 12.7;95%CI 3.01-48.6;p<.001)和肺部疾病(OR 16.1;95%CI 10.4-25.4;p<.001)相关。
- 匹配队列间30天全因死亡率(OR 1.27;95%CI 0.75-2.11;p=.3)和静脉血栓栓塞事件(OR 1.32;95%CI 0.64-2.73;p=.4)无显著差异;但血友病患者住院(OR 1.58;95%CI 1.20-2.10;p=.001)和非中枢神经系统出血事件(OR 4.78;95%CI 2.98-7.48;p<.001)增加。
- 多变量分析中,血友病未减少不良结局(OR 1.32;95%CI 0.74-2.31;p=.2)或静脉血栓栓塞(OR 1.14;95%CI 0.44-2.67;p=.8),但增加出血风险(OR 4.70;95%CI 2.98-7.48;p<.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hypercoagulable state contributing to thrombotic complications worsens COVID-19 severity and outcomes, whereas anticoagulation improves outcomes by alleviating hypercoagulability. OBJECTIVES: To examine whether hemophilia, an inherent hypocoagulable condition, offers protection against COVID-19 severity and reduces venous thromboembolism (VTE) risk in persons with hemophilia (PwH). METHODS: A 1:3 propensity score-matched retrospective cohort study used national COVID-19 registry data (January 2020 through January 2022) to compare outcomes between 300 male PwH and 900 matched controls without hemophilia. RESULTS: Analyses of PwH demonstrated that known risk factors (older age, heart failure, hypertension, cancer/malignancy, dementia, and renal and liver disease) contributed to severe COVID-19 and/or 30-day all-cause mortality. Non-central nervous system bleeding was an additional risk factor for poor outcomes in PwH. Odds of developing VTE with COVID-19 in PwH were associated with pre-COVID VTE diagnosis (odds ratio [OR], 51.9; 95% CI, 12.8-266; p < .001), anticoagulation therapy (OR, 12.7; 95% CI, 3.01-48.6; p < .001), and pulmonary disease (OR, 16.1; 95% CI, 10.4-25.4; p < .001). Thirty-day all-cause mortality (OR, 1.27; 95% CI, 0.75-2.11; p = .3) and VTE events (OR, 1.32; 95% CI, 0.64-2.73; p = .4) were not significantly different between the matched cohorts; however, hospitalizations (OR, 1.58; 95% CI, 1.20-2.10; p = .001) and non-central nervous system bleeding events (OR, 4.78; 95% CI, 2.98-7.48; p < .001) were increased in PwH. In multivariate analyses, hemophilia did not reduce adverse outcomes (OR, 1.32; 95% CI, 0.74-2.31; p = .2) or VTE (OR, 1.14; 95% CI, 0.44-2.67; p = .8) but increased bleeding risk (OR, 4.70; 95% CI, 2.98-7.48; p < .001). CONCLUSION: After adjusting for patient characteristics/comorbidities, hemophilia increased bleeding risk with COVID-19 but did not protect against severe disease and VTE.
引用
- Sharathkumar A, Wendt L, Ortman C, et al. COVID-19 outcomes in persons with hemophilia: results from a US-based national COVID-19 surveillance registry. J Thromb Haemost. 2023. PMID: 37182697. doi:10.1016/j.jtha.2023.04.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。